Very early researchUnknownNCT03815630What this trial is testingPD1 Combined With Dc-cik in the Treatment of Solid TumorsWho this might be right forSolid Tumor Allife Medical Science and Technology Co., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT02997995What this trial is testingDurvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureWho this might be right forBreast CancerEstrogen Receptor Positive TumorMenopause+1 more UNICANCER 61
Early research (Phase 1)Study completedNCT02529072What this trial is testingNivolumab With DC Vaccines for Recurrent Brain TumorsWho this might be right forMalignant GliomaAstrocytomaGlioblastoma Gary Archer Ph.D. 6
Large-scale testing (Phase 3)Active Not RecruitingNCT05374512What this trial is testingDato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Who this might be right forBreast Cancer AstraZeneca 644
Testing effectiveness (Phase 2)Looking for participantsNCT06367075What this trial is testingA Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue SarcomaWho this might be right forAdvanced Soft-tissue Sarcoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT05994001What this trial is testingCandonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 AntibodyWho this might be right forBiliary Tract CancerCandonilimabClaudin 18.2 Shanghai Zhongshan Hospital 78
Testing effectiveness (Phase 2)Looking for participantsNCT06540729What this trial is testingRC48 in Combination With AK104 and Bevacizumab in OCCCWho this might be right forOvary Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 39
Testing effectiveness (Phase 2)Study completedNCT04895137What this trial is testingMFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRCWho this might be right forColorectal CancerImmunotherapy Sixth Affiliated Hospital, Sun Yat-sen University 42
Testing effectiveness (Phase 2)Looking for participantsNCT06923345What this trial is testingModified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)Who this might be right forRectal CancerNeoadjuvant TherapiesImmune Checkpoint Therapy+1 more Sixth Affiliated Hospital, Sun Yat-sen University 80
Not applicableStudy completedNCT03222440What this trial is testingCombination of Radiotherapy and SHR-1210 to Treat Patients With ESCCWho this might be right forEsophageal Cancer Tianjin Medical University Cancer Institute and Hospital 20
Large-scale testing (Phase 3)WithdrawnNCT03342352What this trial is testingNivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)Who this might be right forHead and Neck Cancer Incyte Corporation
Early research (Phase 1)Looking for participantsNCT05338658What this trial is testingStudy of PAT in Patients With Solid Tumor CancersWho this might be right forMetastasisSolid Tumor Masonic Cancer Center, University of Minnesota 21
Very early researchLooking for participantsNCT05916248What this trial is testingCombination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor Ruijin Hospital 34
Testing effectiveness (Phase 2)Looking for participantsNCT07781358What this trial is testingBecotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.Who this might be right forNasopharyngeal Carcinoma (NPC) Hongmeng Yu 25
Testing effectiveness (Phase 2)UnknownNCT05163483What this trial is testingTucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric CancerWho this might be right forEsophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma Ruihua Xu 87
Early research (Phase 1)Active Not RecruitingNCT05334329What this trial is testingGenetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint InhibitorsWho this might be right forAdvanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+8 more University of California, Irvine 6
Large-scale testing (Phase 3)Looking for participantsNCT05236972What this trial is testingPACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal CancerWho this might be right forColorectal Carcinoma Sun Yat-sen University 323
Large-scale testing (Phase 3)Study completedNCT03358472What this trial is testingPembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)Who this might be right forHead and Neck Cancer Incyte Corporation 89
Early research (Phase 1)Study completedNCT04418401What this trial is testingStudy on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC PatientsWho this might be right forHepatocellular Carcinoma Zhejiang University 30
Testing effectiveness (Phase 2)Study completedNCT04428151What this trial is testingLenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)Who this might be right forSquamous Cell Carcinoma of Head and Neck Merck Sharp & Dohme LLC 408